The new production plant was inaugurated today at the company's global pharmaceutical headquarters in
'It is of crucial importance that
The project is part of a billion-dollar investment program through which
'It is great to see a German company like
Bayer's new production facility is based on an innovative platform technology that covers a wide range of chemically and biologically based parenteral products. The highly digitized manufacturing process enables safe, fast, and sterile formulation, filling, and freeze-drying of pharmaceuticals. The highly automated robot-based filling machine combines efficient and reliable production of medications, aiming to bring them from concept to market and ultimately to the patients even faster. The facility serves critical manufacturing areas with high medical demand, such as products in the field of ophthalmology. It is intended to supply markets in the
'The new facility is a significant milestone for our production network. It ensures that high-quality drug forms are available in sufficient quantities, that supply chains become more reliable and efficient and that patients around the world have greater security of supply,' said
The facility is located in
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Contact:
Email: simone.kannapinn@bayer.com
Tel: +49 175 3092113
Email: joline.guenther@bayer.com
Tel: +49 173 4676240
(C) 2023 Electronic News Publishing, source